What do Cancer Moonshot, PMI, Zika and the CARB National Action Plan All Have in Common? Briefing on the basics of laboratory developed tests (LDTs) and the vital role they play in patient care

Tuesday, September 20th 3:00 – 4:00 PM Capitol Visitor Center, SVC 208-09

Agenda

• Opening Remarks Mary Williams, MNA, MT(ASCP)SM, Executive Director, Association for Molecular Pathology

Moderator Introductions

Karen Kaul, MD, PhD, Chair, Department of Pathology and Laboratory Medicine, Duckworth Family Chair, NorthShore University HealthSystem; Clinical Professor of Pathology, University of Chicago Pritzker School of Medicine, Evanston, IL

• Introduction to LDTs

Sherri Bale, PhD, FACMG, Managing Director, GeneDx, Gaithersburg, MD

LDTs in Oncology

Janina A. Longtine, MD, Vice Chair, Pathology and Laboratory Medicine, Yale New Haven Hospital; Immediate Past President; Association for Molecular Pathology

LDTs in Rare Diseases

Marshall Summar, MD, FACMG, Chief, Division of Genetics and Metabolism, Children's National Medical Center, Washington, DC

• LDTs in Infectious Diseases

Angela Caliendo, MD, PhD, Chief, Division of General Internal Medicine, Brown University; Chair, Infectious Diseases Society of America, Diagnostics Task Force

• LDT Policy Overview & Update

Jonathan Nurse, Director of Government Relations, Infectious Diseases Society of America

Questions and Answers

This briefing is sponsored by the American College of Medical Genetics and Genomics, the Association for Molecular Pathology and the Infectious Diseases Society of America